15 results about "Interleukin 12" patented technology

Activatable interleukin 12 (IL12) fusion proteins and constructs are disclosed herein that contain at least one of the following structures: N'-DD-L1-MM-L2-IL12-C', C'-DD-L1-MM-L2-IL12-N', N'-DD-L1-IL12-L2-MM-C', C'-DD-L1-IL12-L2-MM-N', wherein L1 is a first linker or is absent; L2 is a second linker; DD is a dimerization domain; MM is a masking moiety; IL12 comprises an IL12α (p35) domain and an IL12β (p40) domain; N' is an amino terminus of the activatable IL12 fusion protein; and C' is a carboxy terminus of the activatable IL12 fusion protein, wherein at least one of L1 and L2 comprises a cleavable moiety (CM); or a first IL12 subunit and a second IL12 subunit; at least one of a first linking region (LR1) and a second linking region (LR2); and a half-life extending moiety (EM), wherein at least one of the LR1 and the LR2 comprises a cleavable moiety (CM); or dimers thereof.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

Pharmaceutical compositions comprising anti-interleukin 12 (IL-12) interleukin 23 (IL-23) antibodies are described. The pharmaceutical compositions may comprise molecular attributes, such as oxidation of light chain W32, isoaspartic acid at heavy chain position D55; high molecular weight species such as dimers and / or oligomers, high mannose, sialylation, or acidic peak species. Method comprising administering the pharmaceutical compositions are described. Methods of manufacturing the pharmaceutical compositions are described.

The present disclosure relates to multifunctional molecules comprising masked interleukin 12 and methods of making and using the same. In certain embodiments, the multifunctional molecules disclosed herein comprise a cleavable linker.

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.

Provided is a cytokine combination useful for treating a tumor and / or preventing recurrence or metastasis of the tumor. The cytokine combination with at least three cytokines selected from the following groups: interleukin 12 (IL12) or a functional variant thereof, granulocyte-macrophage colony-stimulating factor (GMCSF) or a functional variant thereof, FMS-like tyrosine kinase 3 ligand (FLT3L) or a functional variant thereof, interleukin 2 (IL2) or a functional variant thereof, interleukin 15 (IL15) or a functional variant thereof, interleukin 21 (IL21) or a functional variant thereof, and interleukin 7 (IL7) or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and / or preventing recurrence or metastasis of the tumor.

The invention discloses a nucleic acid molecule delivery carrier as well as a preparation method and application of a freeze-drying preparation of the nucleic acid molecule delivery carrier. Wherein the delivery vehicle comprises a nucleic acid molecule encoding interleukin 12 and an ionizable lipid compound. According to the invention, the mRNA of the interleukin 12 with an optimized sequence is used, the mRNA is more stable, the protein expression is increased, and the misfolding rate is reduced. Meanwhile, the interleukin 12 is anchored through a transmembrane sequence, so that the possible immune storm risk is reduced. Besides, on the basis of newly synthesized, degradable and novel ionizable lipid molecules, a high-efficiency and low-toxicity freeze-drying preparation delivery system based on lipid is formed, and the freeze-drying preparation has potential application value in the fields of preventive vaccines and therapeutic drugs.

The invention provides novel fusion proteins of Interleukin 12 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

Disclosed are an interleukin 12 mutant and the use thereof, belonging to the technical field of genetic engineering. The IL-12 mutant protein comprises a mutated P40 subunit and / or a mutated P35 subunit, wherein the mutated P40 subunit is generated by means of mutating a wild-type P40 subunit at the following positions: positions 37, 38, 39, 40, 81, 82, 106, 108, 114, 115 or / and 219, and the mutation eliminates or reduces the binding affinity of the wild-type P40 subunit for IL-12Rβ1; and the mutated P35 subunit is generated by means of mutating a wild-type P35 subunit at the following positions: positions 72, 151 or / and 190, and the mutation eliminates or reduces the binding affinity for IL-12Rβ2. The IL12 mutant protein and fusion protein can significantly improve a therapeutic effect by means of reducing toxicity and enhancing tumor targeting.

The present disclosure provides surprisingly useful fusion polypeptides including an immunomodulatory moiety and a metal-hydroxide binding moiety, as well as various related technologies, including methods of making and of using such fusion polypeptides.

The present invention addresses the problem of providing an immune cell induced from an iPS cell, which imparts a phenotype that facilitates local migration and infiltration into a solid tumor and proliferation and survival of the immune cell in the solid tumor. [Solution] A cell which is an immune cell induced from an iPS cell and which expresses interleukin 15 and a cell surface molecule that is reactive with a tumor-associated antigen. And a cell which is an immune cell induced from an iPS cell and which expresses a cell surface molecule that is reactive with a tumor-associated antigen and interleukin 12, interleukin 18, or interleukin 21.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

This disclosure relates to a multifunctional molecule containing a shielding interleukin 12, and to methods for fabricating and using the same. In certain embodiments, the multifunctional molecule disclosed herein includes a cleavable linker.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

Provided herein is a recombinant oncolytic virus comprising an oncolytic virus genome comprising a nucleic acid encoding an IL-2 / IL-12 fusion protein. The fusion protein may be membrane-anchored. Also provided are cells expressing the recombinant oncolytic virus as well as method of using the recombinant oncolytic virus and cells described herein, for example for the treatment of cancer. In a preferred embodiment, the oncolytic virus is a vaccinia virus.